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 Abstract 
 Background: The study was conducted to evaluate the 
technical and clinical performance of the VITROS  ®  Immu-
nodiagnostic Products 25-OH Vitamin D Total Assay, and 
compare it with the performance of five marketed auto-
mated assays and a liquid chromatography/mass spec-
trometry reference method (LC-MS/MS). 
 Methods: Three hundred patient serum samples were used 
to compare the correlation of the VITROS  ®  25-OH Vitamin 
D Total   Assay with both the other immunoassays and the 
LC-MS/MS method, using Passing-Bablok  regression and 
Bland-Altman analyses. Concordance of the diagnosis 
of vitamin D status was calculated to test the agreement 
between the different assays. In addition, samples con-
taining vitamin D2 were used to test the assay ’ s ability to 
detect the D2 form of the vitamin. 
 Results and conclusions: These results from the VITROS  ® 
 25-OH Vitamin D Total   Assay generally correlated well 
with those from most of the marketed immunoassays. 
Cross-reactivity of the D2 form was calculated as being 
close to 100%. Additionally, we found substantial vari-
ability in performance amongst the various assays, which 
suggests the need for optimisation and recalibration of 
commercial methods. 
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sion;  vitamin D. 
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 Introduction 
 Vitamin D is classically known for its pivotal role in calcium 
and bone metabolism and is critical for bone and muscle 
health [ 1 ,  2 ]. However, more recent evidence has greatly 
enlarged its importance in more widespread situations, 
especially in extraskeletal diseases such as cardiovascu-
lar disease, autoimmunity and cancer [ 3 – 6 ]. In the body, 
vitamin D is converted, first in the liver to 25-hydroxy-
vitamin D (25-OH D) and then to 1,25-dihydroxy-vitamin D 
(1,25-OH D) in the kidneys [ 7 ]. Though the latter derivative 
is the biologically active form, its relatively short lifetime 
and fluctuation in concentration has supported the inter-
mediate product (25-OH D) as the best indicator of vitamin 
D status [ 8 ]. 
 Vitamin D is present in very few foods, and its 
main source derives from the action of sunlight on 
7- dehydrocholesterol in the epidermis, to produce the form 
vitamin D3. However, a related form, vitamin D2 is also 
ingested from plant sources as well as supplements, and 
both prohormones are equivalently important in defining 
overall vitamin status [ 9 ]. It is therefore important that 
any method of measurement of 25-OH D can detect both 
forms with equal accuracy [ 10 ]. 
 As a result of the acceptance of an increasingly com-
prehensive role for vitamin D in many disease states, the 
demand for 25-OH D testing in the clinical laboratory 
has risen many fold over the last decade. This tendency 
accordingly has forced the transfer of methodologies from 
the academic, laboratory-specific level to rapid through-
put platforms developed by commercial companies. 
 However, this evolution has led to difficulties that 
have appeared in some of these automated assays. Prob-
lems with bias, inconsistency of results, and mutual dis-
agreement between methodologies have arisen [ 10 ,  11 ], 
which have been clearly demonstrated using comparisons 
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with results of liquid chromatography/mass spectrometry 
(LC-MS/MS). 
 Recently, Ortho Clinical Diagnostics (OCD) launched 
an assay for 25-OH Vitamin D on the VITROS  ®  5600 Inte-
grated System and VITROS  ®  3600 and ECi/ECiQ Immu-
nodiagnostic Systems on the European markets. The aim 
of this study was to: 1) evaluate the correlation of the 
VITROS  ®  25-OH Vitamin D Total Assay with five commer-
cially available immunoassays and an LC-MS/MS method; 
2) evaluate the detection of vitamin D2; and 3) assess 
assay precision. 
 Materials and methods 
 Assays 
 The study concentrated on the performance of the VITROS  ®  25-OH 
Vitamin D Total Assay. This method is a competitive, enhanced 
chemiluminescence immunoassay that uses low pH to release the 
25-OH vitamin D in the sample from the binding protein, and uses 
horseradish peroxidase (HRP) labelled 25-OH vitamin D to compete 
with the 25-OH vitamin D in the sample for the binding of the mono-
clonal anti-vitamin D bound to the wells. 
 Other commercially available assays 
1)  Abbott Architect  ®  25-OH Vitamin   D Assay: a delayed one-step 
chemiluminescence method using as capture agent a polyclonal 
anti-vitamin D antibody and a biotinylated vitamin D anti-biotin 
acridinium labelled complex. 
2)  Roche Elecsys  ®  Vitamin D Total Assay: a competitive electro-
chemiluminescence method using a ruthenium labelled vitamin 
D binding protein as capture agent. 
3)  Siemens ADVIA Centaur  ®  Vitamin D Total Assay: a competitive 
chemiluminescence method using a monoclonal acridinium 
labelled anti-25(OH) vitamin D antibody and a vitamin D 
analogue labelled with fluoroscein. 
4)  DiaSorin 25-OH Vitamin D TOTAL Assay: a competitive 
chemiluminescence method using an anti-25(OH)-vitamin D 
antibody where vitamin D and an isoluminol-labelled derivative 
compete for binding run on the Liaison XL platform. 
5)  IDS-iSYS  ®  25-Hydroxy Vitamin D Assay: a competitive 
chemiluminescence method using an anti-25(OH) vitamin D 
antibody conjugated with acridinium, with 25-(OH) vitamin D 
conjugated to magnetic particles. 
6)  The liquid chromatography and tandem mass spectrometry 
(LC-MS/MS) method was carried out using the Perkin Elmer 
methodology as described earlier [ 11 ]. Briefly, analyses were 
performed using a triple quadripole TQ5500 from ABSciex 
(Framingham, MA, USA) with Atmospheric Pressure Chemical 
Ionisation (APCI) source. Calibration was performed using six 
calibrator points [charcoal stripped human serum enriched 
with increasing levels of  2 H 6 -25(OH)D 2 and  2 H 6 -25(OH)D 3 ]. 
Three control levels [lyophilised serum added with increasing 
amount of  2 H 6 -25(OH)D 2 and  2 H 6 -25(OH)D 3 ] were used as quality 
controls. For each analyte specific isotopically labelled internal 
standards [ 2 H 3 -25(OH)D 2 for VitD 2 and  2 H 3 -25(OH)D 3 for VitD 3 ] 
were used. To 100  μ L of serum sample, calibrator or control, 
200  μ L of daily precipitation solution (DPS, prepared by 
diluting reconstituted Internal Standard 1/100 with acetonitrile 
containing 0.1% of formic acid) was added. The samples were 
mixed for 15 min and then centrifuged at 16,000  g for 15 min at 
4 ° C. Finally, 150  μ L of supernatant was transferred into a 96-well 
plates. The plate was loaded in the autosampler, and 50  μ L were 
injected into the HPLC-MS/MS system. Limit of quantification 
(LOQ) was 2.43 ng/mL for 25-OHD 2  and 3.40 ng/mL for 25-OHD 3 . 
The intra-assay CV was  < 7.2% and  < 10%, and inter-assay CV 
was  < 7.9% and  < 8.9% for three concentrations between 7.5 and 
78.1 ng/mL for 25-OHD 2 and 25-OHD 3 , respectively. The linearity 
range of 25-OHD 2 and 25-OHD 3 was 2.43 to 329 and 3.40 to 
314 ng/mL, respectively. In addition, we have controlled 
the calibration of the method with the NIST standards and 
participate to DEQAS, and the results were always on the target 
for LC-MS/MS users. 
 Samples 
 Serum samples from 300 patients were used to determine cross-
correlation and concordance between methods. These were residual 
laboratory samples, blinded to patient identifi cation and informa-
tion. The samples contained vitamin D concentrations, as measured 
by LC-MS/MS, ranging from 4.6 to 105 ng/mL. All samples were ali-
quoted and frozen at  − 20 ° C until required for testing. One aliquot of 
each sample was tested in each assay. The ability of assays to detect 
vitamin D2 was tested using samples obtained in patients on D2 
therapy. 
 Statistics 
 The correlation of the VITROS  ®  25-OH Vitamin D Total Assay results 
with those of the other assays was analysed using Passing-Bablok 
regression. The correlation coeffi  cient was calculated using the Pear-
son ’ s correlation method. The slope and intercept are referred to in 
the text as proportional and constant bias, respectively. Assay biases 
were also calculated using the Bland-Altman plot. The same meth-
ods were used to determine agreement of all the commercial assays 
against LC-MS/MS. 
 Agreement of vitamin D status between methods was calcu-
lated using concordance tables. Briefl y, this involved classifi cation 
of patients according to their vitamin D concentrations:  < 20 ng/mL, 
20 – 30 ng/mL, 30 – 80 ng/mL and  > 80 ng/mL, and then determining 
the percentage of patients classifi ed correctly by any two methods. 
 In order to determine whether there were any methodologi-
cal diff erences in the detection of D2, a panel of 11 samples with D2 
and D3 concentrations as measured by LC-MS/MS. D2 concentra-
tions ranged from 21 to 48.1 ng/mL (mean ± SD: 36 ± 8 ng/mL) and D3 
concentrations ranged from 5 to 30 ng/mL (mean ± SD: 15 ± 8 ng/mL). 
The samples were tested in both, the LC-MS/MS (D3 and D2) and the 
VITROS, Liaison, ISYS, Architect and Elecsys assays. The percentage 
of 25(OH)D2 recovery was evaluated with a slightly modifi ed proto-
col, as previously published in this journal [ 11 ,  12 ]. 
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 Figure 1   Correlation and bias of vitamin D assay results from the VITROS assay against the five other commercial assays and the LC-MS method. 
 Left column: correlation diagrams, right column, bias of results against VITROS for each assay over a span of vitamin D concentrations. 
y-Axis (left column): VITROS vitamin D values ng/mL; x-axis (left column) vitamin D concentrations measured by each commercial assay. 
y-axis (right column): Bias of commercial assays against VITROS results; x-axis: mean vitamin D estimate from LC-MS/MS and assay deter-
mination for each sample. 
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 We evaluated the precision of the VITROS  ®  25-OH Vitamin D 
Total Assay in accordance with a modifi ed protocol based on the 
evaluation of precision performance CLSI EP-5A2. Six sample pools 
(vitamin D range of 6.57 to 102 ng/mL) were tested in triplicate for 5 
days, within a single calibration period. 
 Results 
 Correlation of VITROS  ®  25-OH Vitamin D Total 
Assay results with those from marketed 
assays and an LC-MS/MS method 
 Comparison of the VITROS  ®  25-OH Vitamin D Total Assay 
results on the 300 patient serum samples with all the other 
methods using Passing-Bablok regression and Bland-Altman 
plots is shown in  Figure 1.  Table 1 displays the correlation 
statistics of the VITROS  ®  25-OH Vitamin D Total Assay 
results (y-axis) against the results from the other com-
mercial vitamin D assays and the LC-MS/MS method. The 
results from the VITROS  ®  25-OH Vitamin D Total Assay cor-
related well with those from the other assays, with slopes 
ranging from 0.80 to 1.06, intercept  − 3.5 to 4.7 ng/mL, 
and correlation value from 0.85 to 0.92. 
 When the VITROS  ®  25-OH Vitamin D Total   Assay 
results were compared with those from the LC-MS/MS 
method, a negative bias was revealed. To quantify such 
biases, the LC-MS/MS results were also compared with 
those of the other assays. 
 In  Figure 2 , the correlations between LC-MS/MS 
results and those of Vitros  ®  and the other commercial 
assays are depicted using Passing-Bablok regression and 
Bland-Altman plots. 
 Table 2 shows the correlation statistics of the LC-
MS/MS results (x-axis) against the results obtained by all 
the commercial Vitamin D assays. Almost all the assays 
were negatively biased when compared to the LC-MS/MS 
method, both with the proportional slopes (varying from 
0.76 to 0.93) and with constant biases (intercepts varying 
from  − 6.0 to 3.9). The correlation coefficients ranged from 
0.84 (Liaison) to 0.92 (Centaur). 
 These results clearly demonstrated the variability in 
test results from different assays. To evaluate the potential 
impact on this discordance on the accurate determination 
of a patient ’ s vitamin D status, the agreement of assign-
ment of vitamin D status by different assays was calcu-
lated.  Table 3 shows the percentage concordance between 
methods in the patient samples tested. The concord-
ance between methods was variable, ranging from 65% 
(concordance between LC-MS/MS and Centaur) to 83% 
(Liaison vs. Architect). Concordance against LC-MS/MS 
varied from a low of 65% (Centaur) to a high of 82% (ISYS). 
 Vitamin D2 detection 
 Recovery of 25(OH)D2 by the Liaison, ISYS, VITROS and 
Roche assays was not significantly different from 100%. 
The median (95% CI) percentage recovery for each method 
was 102 (87 – 113)%, 104 (84 – 119)%, 106 (83 – 132)% and 78 
(68 – 110)%, respectively. Even though the median of the 
percentage 25(OH)D2 recovery obtained with the Architect 
was similar to the one observed with Elecsys (78%), the 
95% confidence interval was 64% to 81%, which did not 
encompass 100%. 
 VITROS  ®  25-OH Vitamin D Total   Assay 
precision 
 The precision of the assay over 5  days with six serum 
pools is shown in  Table 4 . This varied from 4.1% for the 
102 ng/mL pool to 21.7% for the 6.57 ng/mL pool. 
 Discussion 
 The present study was designed to evaluate the technical 
and clinical performance of the VITROS  ®  Immunodiag-
nostic Products   25-OH Vitamin D Total   Assay. Our results 
demonstrated that this new assay generally correlated 
well with the five other marketed vitamin D immunoas-
says and the LC-MS/MS method. We also examined its 
cross reactivity with the D2 form of the vitamin and found 
a satisfactory performance in this regard. The precision 
profile of the VITROS  ®  25-OH Vitamin D Total   Assay was 
comparable with those of the other commercial assays 
over the assay ’ s measuring range (8 – 150 ng/mL). 
 Table 1   Correlation statistics of the VITROS 25-OH Vitamin D Total 
Assay results (y-axis) against the results obtained in the Perkin 
Elmer LC-MS/MS and the other commercial assays (x-axis). 





 LC-MS/MS  0.80 (0.76 – 0.84)  − 0.5 ( − 2.2 – 1.2)  0.90 
 Architect  0.94 (0.88 – 1.01)  0.1 ( − 2.1 – 1.6)  0.85 
 Centaur  0.84 (0.79 – 0.89)  4.7 (2.7 – 7.1)  0.88 
 Liaison  1.06 (1.00 – 1.12)  − 2.2 ( − 0.3.9 –  – 0.3)  0.89 
 Elecsys  0.94 (0.90 – 0.99)  − 0.7 ( − 2.1 – 0.9)  0.92 
 iSYS  0.97 (0.91 – 1.04)  − 3.5 ( − 6.2 –  −  1.1)  0.85 
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 Figure 2   Correlation and bias of vitamin D assay results from LC-MS/MS against the VITROS assay and five other commercial assays. 
 Left column: correlation diagrams, right column, bias of results against LC-MS/MS for each assay over a span of vitamin D concentrations. 
y-Axis (left column): LC-MS/MS vitamin D. Values ng/mL; x-axis (left column) vitamin D concentrations measured by each commercial assay. 
y-Axis (right column): bias of commercial assays against LC-MS/MS; x-axis: mean vitamin D estimate from LC-MS/MS and assay determina-
tion for each sample. 
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 Our results showed that there are significant meth-
odological differences between assays as demonstrated 
by the different correlation statistics (significant propor-
tional and constant biases and variable correlation coeffi-
cients) and variable inter-method concordance (from 65% 
to 83%). However, many of the discordances arose from 
readouts close to the status cut-off points. For example 
a value of 29 ng/mL by one method was considered as 
vitamin-deficient, whilst a value of 30.5 ng/mL by a dif-
ferent method was considered vitamin-sufficient. Whilst 
these small differences in the methods may put patients 
into different vitamin D status categories, such discord-
ances may not affect patient management. Nevertheless, 
much larger discrepancies in vitamin D estimations were 
found, the size of which could affect patient management. 
Accordingly, method standardisation is urgently required 
in the field of vitamin D measurement. In addition, dis-
crepancy in methods could be caused by cross-reactivity 
to various vitamin D2 and D3 metabolites such as the C3 
epimer or by interferences from agents such as haemo-
globin, human anti-mouse antibodies (HAMAs) or het-
erophilic antibodies. It is therefore important for clinical 
laboratories to be aware of the limitations of their assay. 
 (25-OH) vitamin D determination in serum by immu-
noassays is a difficult task owing to the fact that it circu-
lates in a form strongly bound to binding proteins, and it 
exists in different forms [25(OH)D2 and 25(OH)D3], whose 
relative concentrations depend on either diet or the exact 
 Table 2   Correlation statistics of the LC-MS/MS results (x-axis) 
against the results obtained by all the commercial vitamin D assays 
(y-axis). 





 Architect  0.85 (0.80 – 0.90)  − 0.6 ( − 2.6 – 1.4)  0.87 
 Liaison  0.76 (0.73 – 0.79)  1.4 (0.3 – 2.6)  0.84 
 Centaur  0.93 (0.89 – 0.98)  − 6.0 ( − 8.3 –   − 4.0)  0.92 
 iSYS  0.81 (0.77 – 0.85)  3.9 (2.3 – 5.3)  0.91 
 VITROS  0.80 (0.76 – 0.84)  − 0.5 ( − 2.2 – 1.2)  0.90 
 Elecsys  0.85 (0.81 – 0.89)  − 0.7 ( − 2.3 – 1.08)  0.91 
 Table 3   Concordance of vitamin D status between methods (expressed as %). 
  LC-MS/MS  Centaur  ISYS  Elecsys  Architect  VITROS  DiaSorin XL 
 LC-MS/MS  –  65  82  75  76  72  72 
 Centaur  65  –  68  74  79  78  83 
 ISYS  82  68  –  77  80  75  79 
 Elecsys  75  74  77  –  82  81  81 
 Architect  76  79  80  82  –  80  85 
 VITROS  72  78  75  81  80  –  82 
 DiaSorin XL  72  83  79  81  85  82  – 
 Table 4   Precision of the VITROS  ®  25-OH Vitamin D Total Assay. 
  Pool 1 a  Pool 2  Pool 3  Pool 4  Pool 5  Pool 6 
 Mean, ng/mL  6.57  19.6  31.7  45.6  60.2  101.8 
 % CV  21.7%  6.1%  8.4%  7.1%  6.8%  4.1% 
 a This level is below the VITROS assay limit of quantitation (LOQ). 
method of vitamin D supplementation. A standardisation 
of the methods is thus urgently needed and is currently 
ongoing, through the Vitamin D Standardization Program 
(VDSP) [ 13 ,  14 ]. This work is managed by the NIH Office 
of Dietary Supplements (ODS) in collaboration with the 
CDC National Center for Environmental Health (NCEH), 
the National Institute of Standards and Technology (NIST) 
and the Ghent University. It is thus anticipated that a rec-
alibration of the different methods will occur. When this 
standardisation will be eventually completed, another 
challenge will be to evaluate whether the clinical cut-offs 
currently defining vitamin D deficiency/insufficiency are 
still valid or need to be updated. 
 In conclusion, the analytical performances of the 
VITROS assay, as demonstrated in this study, show that 
this method performs satisfactorily. 
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